SLC22A13 (OAT10) is an organic anion antiporter that mediates bidirectional transport of urate, orotate, and nicotinate across cell membranes 1. In the kidney, SLC22A13 localizes to the apical membrane of proximal tubule epithelial cells where it functions as a renal urate reabsorber, transporting urate from the tubular lumen in exchange for organic anions such as lactate and glutathione 2. The transporter also localizes to the basolateral membrane of type A intercalated cells in the collecting duct, where it mediates unidirectional efflux of aspartate and glutamate 3. Transport of urate and orotate is chloride-dependent 42. SLC22A13 exhibits similar transport characteristics to URAT1 (SLC22A12) and may compensate for URAT1 dysfunction under certain conditions. Functionally, SLC22A13 can be physically coupled to monocarboxylate transporter MCT1, affecting its substrate selectivity 5. Clinically, loss-of-function variants (rs117371763, p.R377C and p.R16H) are associated with reduced serum urate levels and increased renal urate excretion, providing protection against gout 26. Reduced SLC22A13 expression correlates with advanced clinical stage and poor prognosis in clear cell renal cell carcinoma 7. As a renal urate reabsorber, SLC22A13 represents a potential pharmacological target for urate-lowering therapy, with some uricosuric drugs like losartan and lesinurad showing inhibitory effects 2.